Company intelligence / Profile preview

Timber Pharmaceuticals, Inc.

Madison, New Jersey, United Statesleo-pharma.com ↗

Ownership: Private
Employees: ~1
Development stage: Phase 3

Overview

Timber's lead candidate TMB-001 failed to meet primary and key secondary endpoints in the Phase 3 ASCEND trial for congenital ichthyosis announced in August 2024. The trial results did not support submission of a New Drug Application to the FDA.

Therapeutic areas: Dermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

isotretinoin

Phase 3

Indications: Congenital ichthyosis

Partnerships

LEO Pharma A/S

Beyond the preview

Go deeper on Timber Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Timber Pharmaceuticals, Inc..

Explore the full profile